ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1087

Identification of Novel Proteomic Biomarkers of Disease Activity in ANCA-Associated Vasculitis Using a High Throughput Approach

Zachary Wallace1, Amit Joshi1, Xiaoqing Fu1, Claire Cook1, yuqing zhang2 and Hyon Choi3, 1Massachusetts General Hospital, Boston, MA, 2Massachusetts General Hospital, Quincy, MA, 3MASSACHUSETTS GENERAL HOSPITAL, Lexington, MA

Meeting: ACR Convergence 2022

Keywords: ANCA associated vasculitis, Genomics and Proteomics, proteomics

  • Tweet
  • Email
  • Print
Session Information

Date: Sunday, November 13, 2022

Title: Vasculitis – ANCA-Associated Poster II: Treatment Efficacy, Clinical Outcomes, Biomarkers

Session Type: Poster Session B

Session Time: 9:00AM-10:30AM

Background/Purpose: ANCA-associated vasculitis (AAV) is associated with excess morbidity and mortality. Identifying novel biomarkers may reveal new therapeutic targets and clinically useful biomarkers of disease activity to personalize management. ANCA is the most used biomarker of disease activity in AAV but poorly predicts future disease activity. Previous studies investigated protein signatures of disease activity using a small panel of candidate markers. We leveraged a high-throughput approach to identify potential biomarkers in AAV.

Methods: Serum samples from patients in the Mass General Brigham (MGB) AAV cohort were retrieved from the MGB Biobank or a prospective biorepository. We chose a random 78 who had ANCA+ AAV. We classified disease activity (Active/Remission) at sample collection. We determined whether a clinical ELISA test for MPO- or PR3-ANCA was performed when the sample was collected; if so, we extracted the titer and reference ranges. We used the Olink high-throughput assay for 92 inflammatory proteins (Table 1). We compared the concentration of each protein among (1) active disease vs remission; (2) ANCA positive vs negative; and (3) ANCA positive vs negative among those in remission. We used unadjusted and age- and sex-adjusted linear regression to compare normalized protein levels across groups. Adjustment for multiple comparisons was based on the 10% false discovery rate (FDR) procedure.

Results: Of 78 subjects, the mean age was 56.8 (SD17.6), 56% were female, 44% were MPO-ANCA+, and 28% had active disease at sample collection. 65 patients had an ANCA ELISA available, 45 of whom were in remission. Of the 92 proteins assessed, 88 were analyzed. After adjusting for multiple comparisons (Table 2), three proteins differentiated those with active disease from those in remission: monocyte chemotactant protein (MCP)-3 (adjusted B coefficient 0.74 (95%CI 0.31 to 1.17), FDR-adjusted p=0.036), stem cell factor (SCF, -0.82 (95%CI -1.28 to -0.35), p=0.036), and tumor necrosis factor superfamily member (TNF-SF)-14 (0.63 (0.22 to 1.03), p=0.048). Three proteins differentiated patients with a positive ANCA vs negative ANCA: Axin 1 (0.79 (0.32 to 1.26), p=0.04), Interleukin (IL)-12B (-0.90 (-1.46 to -0.33), p=0.04), and Sirtuin (SIRT)-2 (0.79 (0.30 to 1.29), p=0.04). Among those in remission, those with a positive ANCA were distinguished from those with a negative ANCA by IL-12B (-1.02 (95%CI -1.55 to -0.49), p=< 0.001).

Conclusion: Using a high-throughput approach, we identified novel candidate markers differentiating active disease from remission and positive vs negative ANCA. These proteins reflect diverse aspects of the immune response. The potential for biomarkers that distinguish ANCA positive from negative status, especially among people in remission, suggests that patients in clinical remission with persistently positive ANCA may have ongoing inflammation that could contribute to subclinical damage. Indeed, a prior study found that IL-12 production by dendritic cells was decreased in patients with active vs remission AAV. These findings require validation in additional cohorts, using longitudinal serial samples, and confirmatory methods.

Supporting image 1

Supporting image 2


Disclosures: Z. Wallace, Sanofi, Bristol-Myers Squibb(BMS), Zenas Biopharma, Shionogi, Horizon; A. Joshi, Regeneron Inc; X. Fu, None; C. Cook, None; y. zhang, None; H. Choi, Horizon, Allena, LG, Protalix.

To cite this abstract in AMA style:

Wallace Z, Joshi A, Fu X, Cook C, zhang y, Choi H. Identification of Novel Proteomic Biomarkers of Disease Activity in ANCA-Associated Vasculitis Using a High Throughput Approach [abstract]. Arthritis Rheumatol. 2022; 74 (suppl 9). https://acrabstracts.org/abstract/identification-of-novel-proteomic-biomarkers-of-disease-activity-in-anca-associated-vasculitis-using-a-high-throughput-approach/. Accessed .
  • Tweet
  • Email
  • Print

« Back to ACR Convergence 2022

ACR Meeting Abstracts - https://acrabstracts.org/abstract/identification-of-novel-proteomic-biomarkers-of-disease-activity-in-anca-associated-vasculitis-using-a-high-throughput-approach/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology